title: Analysis of the methylation status of genes up-regulated by the demethylating agent, 5-aza-2'-deoxycytidine, in esophageal squamous cell carcinoma.
abstract: To determine the clinical significance of gene promoter methylation in esophageal squamous cell carcinoma (ESCC), we examined the promoter methylation status of genes showing elevated expression, as determined by DNA microarray-based transcriptomic analysis, in three ESCC cell lines (TE-1, TE-2, TE-10) after 5-aza-2'-deoxycytidine (DAC) treatment. We observed a high degree of DNA methylation within the promoter regions of three genes, namely cathepsin L2 (CTSL2), normal mucosa of esophagus specific 1 (NMES1), and fatty acid binding protein 5 (FABP5). Overexpression of NMES1 in ESCC cell lines increased cell motility. Down-regulation of NMES1 might play an important role in the cell motility of ESCC or be a potent marker of malignancy.
authors.affiliation: Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan. araim-cib@umin.ac.jp
authors.forename: Makoto
authors.initials: M
authors.lastname: Arai
authors.forename: Fumio
authors.initials: F
authors.lastname: Imazeki
authors.forename: Yuzo
authors.initials: Y
authors.lastname: Sakai
authors.forename: Rintaro
authors.initials: R
authors.lastname: Mikata
authors.forename: Motohisa
authors.initials: M
authors.lastname: Tada
authors.forename: Naohiko
authors.initials: N
authors.lastname: Seki
authors.forename: Hideaki
authors.initials: H
authors.lastname: Shimada
authors.forename: Takenori
authors.initials: T
authors.lastname: Ochiai
authors.forename: Osamu
authors.initials: O
authors.lastname: Yokosuka
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D056668:Cathepsin L; D002403:Cathepsins / Q000235:genetics / Q000378:metabolism; D018797:Cell Cycle Proteins / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D003546:Cysteine Endopeptidases / Q000235:genetics / Q000378:metabolism; D019175:DNA Methylation / Q000187:drug effects*; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors; D000077209:Decitabine; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D004947:Esophagus / Q000378:metabolism; D050556:Fatty Acid-Binding Proteins / Q000235:genetics / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D009363:Neoplasm Proteins / Q000235:genetics* / Q000378:metabolism; D009687:Nuclear Proteins / Q000235:genetics* / Q000378:metabolism; D011401:Promoter Regions, Genetic / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000097642:GADD45 Proteins
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine; D056668:Cathepsin L; D002403:Cathepsins; D018797:Cell Cycle Proteins; D003546:Cysteine Endopeptidases; D015254:DNA Modification Methylases; D000077209:Decitabine; D050556:Fatty Acid-Binding Proteins; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D012333:RNA, Messenger; C493412:FABP5 protein, human; C439070:GADD45A protein, human; D000097642:GADD45 Proteins; C465665:C15orf48 protein, human; C534281:CTSL protein, human